Can T-DM1 Match Chemotherapy Plus Dual Blockade in HER2+ Breast Cancer?

A phase II trial tested docetaxel, trastuzumab, and pertuzumab vs T-DM1 for the neoadjuvant treatment of HER2+ breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news